Gyre Therapeutics
GYRE
31 hedge funds and large institutions have $1.04M invested in Gyre Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
30% more capital invested
Capital invested by funds: $796K → $1.04M (+$240K)
11% more funds holding
Funds holding: 28 → 31 (+3)
0.02% less ownership
Funds ownership: 0.4% → 0.38% (-0.02%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$92.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.4K |
| 3 |
Morgan Stanley
New York
|
+$9.66K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$8.95K |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$4.84K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$82K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$35.8K |
| 3 |
VF
Virtu Financial
New York
|
-$17K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$11.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $1.94K | +$1.22K | +182 | +212% |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $188 | +$80 | +12 | +86% |
|
28
BNP Paribas Financial Markets
Paris,
France
| $134 | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $97 | – | – | – |
|
30
Qube Research & Technologies (QRT)
London,
United Kingdom
| $11 | +$7 | +1 | New |
|
|
VF
31
Virtu Financial
New York
| – | -$17K | -3,242 | Closed |
|
|
KWM
32
Keebeck Wealth Management
Chicago,
Illinois
| – | -$7.03K | -1,333 | Closed |
|
|
CSS
33
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$5.16K | -979 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$114 | +17 | New |
|
GYRE Hedge Fund Activity: Q3 2023 in Review
31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2023, worth a combined $1.04M — up 30% from $796K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GYRE positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $92.4K. The largest seller was Renaissance Technologies, cutting an estimated $82K.
- 31 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2023, up from 28 in Q2 2023.
- Funds reported $1.04M of Gyre Therapeutics stock for Q3 2023, up 30% quarter-over-quarter.
- 6 funds opened new Gyre Therapeutics positions in Q3 2023 and 3 closed out, a net change of +3 holders.
- The largest Gyre Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $92.4K added.
- The largest Gyre Therapeutics seller in Q3 2023 was Renaissance Technologies, an estimated $82K sold.
Based on aggregated 13F filings for Q3 2023.